~~<i id='02CF310D18'><strike id='02CF310D18'><tt id='02CF310D18'><pre id='02CF310D18'></pre></tt></strike></i>~~

Home» knowledge» focus

focus

author：knowledge 2025-09-27 17:00:42 Page View：3

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What AAP's gender
Next article： Moonlake's readout produced a cash windfall. Risks remain

explore

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

What the Wegovy shortage looks like for doctors — and for patients

Afterphysicallydebilitatingcancertreatment,LaurieBrunnerencounteredanothermedicalhurdle:Shehaddevelo

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

NYU Langone launches private ChatGPT for its health care data

VincentMajor(left)andCristinaGonzalezattheprompt-a-thonorganizedbyNYULangone.CourtesyJoeCarrotta/NYU

WSS

focus

focus

comprehensive

explore

NYU Langone launches private ChatGPT for its health care data